

1 Characteristic and Outcomes of Patients with ST-segment Elevation
2 Myocardial Infarction who have Non-System Reasons for Delay in
3 Treatment: A Report from the AHA GWTG CAD Registry

4 Tetz C. Lee¹, James G. Jollis^{2,3}, Haoyun Hong⁴, Tian Jiang⁴, Juan Zhao⁴, Timothy D. Henry²,
5 Alice K. Jacobs⁵, Abhinav Goyal⁶, Christopher B. Granger³, Kathie Thomas⁴, and Jacqueline E
6 Tamis-Holland⁷

- 7
8 1. Mount Sinai Morningside, New York, New York
9 2. The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital,
10 Cincinnati, Ohio
11 3. Duke University, Durham, North Carolina
12 4. American Heart Association, Dallas, Texas
13 5. Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts
14 6. Emory University School of Medicine, Department of Medicine, Division of Cardiology,
15 Atlanta, Georgia
16 7. Cleveland Clinic, Cleveland, Ohio
17
18

1 Abstract

2 **Background:** The past two decades have witnessed reductions in time to diagnosis and
3 reperfusion therapy in patients with ST elevation myocardial infarction (STEMI), largely through
4 improvements in STEMI systems of care. While studies have demonstrated important benefits of
5 timely coronary reperfusion in STEMI patients, those with non-system reasons for delay (NSD)
6 are often excluded from these analyses, limiting insights into the overall quality of care for these
7 patients.

8 **Methods:** We analyzed the NSD in patients with STEMI undergoing primary PCI who were
9 enrolled in the GWTD-CAD registry from January 1st, 2019, to December 31st, 2021. We
10 examined the patient-level characteristics and outcomes for patients with and without reported
11 NSD. We performed multivariable logistic regression models to examine the association between
12 NSD and in-hospital mortality, adjusting for patient demographics, clinical variables, and social
13 factors. We then categorized hospitals into four groups based on proportion of STEMI patients
14 with NSD and examined the hospital-level characteristics across the quartiles. We further
15 grouped hospitals by quality metric achievement of timely coronary reperfusion and examined
16 the rates of NSD and treatment times for each category of achievement of the quality metric.

17 **Results:** 74,372 patients were included in the study. 17,741 (23.9%) patients were reported to
18 have NSD. Patients with NSD were older, and more likely to be female, of Black race, and have
19 significant comorbidities including higher rates of cardiac arrest, heart failure and cardiogenic
20 shock on presentation. In-hospital mortality rate was significantly higher in patients with NSD
21 (15.4% vs 2.7%), (Adjusted OR 2.78, [95% CI:2.54-3.04]). Although high-achieving hospitals
22 (those meeting the metrics $\geq 75\%$) excluded more patients, they consistently maintained shorter
23 treatment times, even when NSD patients were included in the analysis.

24 **Conclusion:** NSD in STEMI care is prevalent and linked to higher in-hospital mortality. While
25 concerns about selective case exclusion exist, high-achieving hospitals consistently demonstrated
26 excellent time-to-treatment even when patients with NSD are included.

1 Background

2 The past two decades have witnessed considerable advances in the management of patients with
3 ST elevation myocardial infarction (STEMI)¹⁻⁴. The American Heart Association's Mission:
4 Lifeline program, created in 2008, provides a framework for managing these patients across the
5 systems of care and encourages communication and coordination between emergency medical
6 services (EMS), hospital emergency departments and the cardiac catheterization laboratories.
7 The Get With The Guidelines–Coronary Artery Disease (GWTG-CAD) registry was developed
8 to allow health care systems to monitor the time to treatment, therapies provided and hospital
9 outcomes of patients with acute myocardial infarction (AMI). For STEMI patients, this data
10 provides a perspective of management across the EMS and hospital systems. Numerous studies
11 have shown that timely coronary reperfusion in STEMI patients reduces in-hospital and long-
12 term mortality⁵⁻⁹. However, patients with non-system reasons for delay (NSD) were excluded
13 from the most recent and comprehensive analysis⁹.

14 Exclusion criteria were originally designed to preserve the face validity of quality
15 improvement measures by excluding patients whose treatment times were due to uncontrollable
16 delays. In the case of STEMI care, patients with NSD were not included in the measures of door-
17 to-balloon time for the purposes of public or proprietary quality improvement initiatives. An
18 earlier study based on the CAD-GWTG registry from 2009 to 2011 reported a frequency of NSD
19 of 15% and identified five-fold higher mortality (3% versus 15%) for patients with NSD¹⁰. The
20 report raised concerns that a significant portion of STEMI patients were excluded from quality
21 improvement assessment and urged that future reports provide a more detailed analyses to
22 potentially expand the focus of the quality-of-care initiatives to include those with NSD. Despite
23 this call to action, the number and frequency of exclusions for NSD has increased over time. In a
24 recent analysis, the proportion of patients with STEMI reported as having NSD in the GWTG-
25 CAD registry increased from 19% to 24% between 2018 and 2021¹¹. Notably earlier reports have
26 demonstrated great variation in reporting of NSD on a hospital level ranging from from 0% to
27 68%, with an interquartile range of 6% to 14%¹². Studies from matching hospitals noted a two-
28 fold variation in exclusion rates depending on the registry to which the hospital is reporting.¹³
29 This variation raises the possibility that the approach to quality improvement may rely on
30 identifying reasons for exclusion more than identifying opportunities for improvement¹²⁻¹⁴.

1 Using a national registry of patients with STEMI, we sought to determine the proportion of
2 STEMI patients reported as having NSD and examine the outcomes of these patients. We
3 hypothesized that important opportunities for improved quality of care and outcomes can be
4 identified through a more thorough understanding of NSD.

5

6 [Methods](#)

7 [Data collection](#)

8 We analyzed the data from the GWTG-CAD registry a national quality improvement
9 registry of patients with acute myocardial infarction. The American Heart Association GWTG-
10 CAD Registry is a voluntary quality improvement program in the United States which has been
11 described previously⁹. Participating hospitals upload clinical data of consecutive patients
12 admitted with ST-elevation myocardial infarction (STEMI) or NSTEMI. Program information
13 and data elements collected in the case report form are available at:
14 <https://www.heart.org/en/professional/quality-improvement>. Because data were used primarily at
15 the local site for quality improvement, each participating hospital received either human research
16 approval to enroll cases without individual patient consent under the common rule, or a waiver of
17 authorization and exemption from subsequent review by their institutional review board (IRB).
18 Advarra, the IRB for the American Heart Association, determined that this study is exempt from
19 IRB oversight. The data collection and coordination for GTWG programs are managed by
20 IQVIA (Parsippany, New Jersey).

21 [Study population](#)

22 For the purposes of this analyses, we examined patients enrolled in the GWTG-CAD
23 registry with acute STEMI referred for primary percutaneous coronary intervention (PCI).
24 Exclusion criteria include patients who received fibrinolysis; who underwent PCI more than 12
25 hours from symptom onset and were not unstable; or had PCI for NSTEMI. The study evaluated
26 consecutive patients enrolled in the registry between January 1st, 2019, and December 31st,
27 2021. We grouped patients according to the presence or absence of NSD. We further classified
28 patients with NSD into two groups: those whose reasons were due to cardiac arrest, the need for

1 intubation, or placement of an LV support device, and those whose reasons were unrelated to
2 cardiac arrest, intubation, or the need for LV support device placement.

3 Outcomes

4 The outcomes of interest included time to reperfusion for STEMI and in-hospital mortality.
5 Given that the time to reperfusion varied depending on transportation modes, the outcome
6 measure was defined separately for each presentation mode. First medical contact was defined
7 according to the setting where patients first presented. For those presenting by EMS to a PCI-
8 capable hospital, it was defined as the time they were first evaluated by paramedics; for those
9 who walked in to a PCI-capable hospital, it was defined as the hospital arrival time; and for those
10 requiring interhospital transfer for PCI, it was defined as the time they arrived at the referring
11 hospital. Each outcome were calculated using the published measure defined in STEMI
12 Receiving Center Achievement, Quality, and Reporting Measures (Version 12/2019)^{15 16}. Briefly,
13 the primary objective of the quality program was to provide coronary artery reperfusion (device
14 time) for 75% of patients within 90 minutes of first medical contact for patients initially
15 presenting to PCI-capable hospitals, and 120 minutes for patients requiring hospital transfer for
16 PCI. The goal for each of these outcomes was derived based on the ACC-AHA guidelines.

17 Statistical Analyses

18 To evaluate difference between the patient-level characteristics for patients with and without
19 NSD, we used the chi-square test if appropriate for categorical variables and Kruskal-Wallis test
20 for continuous variables. Multivariable logistic regression modeling using generalized estimating
21 equations was conducted to evaluate if NSD were independent predictors of in-hospital mortality
22 accounting for within-hospital correlation. Patients without reported NSD served as the reference
23 group. The adjusted models included demographics (age, sex, race, and ethnicity) at admission,
24 medical history, and illness severity descriptors such as cardiac arrest prior to arrival, cardiogenic
25 shock on first medical contact (FMC), and heart failure on FMC. We also conducted another
26 adjusted model with adjusting all the above variables plus the social variables including
27 insurance and Social Vulnerability Index (SVI)¹⁷. These adjusted covariates were used based on
28 a prior study¹¹. We reported the in-hospital mortality rates, the odds ratio (OR) in unadjusted and
29 adjusted models. Statistical significance was assessed at a 2-sided $\alpha = .05$. Patients at sites with

1 missing hospital characteristics were excluded from models. The missing values for clinical
2 continues variables were imputed using multiple imputation techniques (e.g. multiple imputation
3 by chained equations).

4 For our second analysis, we categorized hospitals into quartiles based on proportion of STEMI
5 patients excluded from their analysis for treatment times due to NSD. We examined hospital
6 level characteristics across these quartiles. Between-group differences were assessed using the
7 chi-square test or Fisher's exact test if appropriate for categorical variables and Kruskal-Wallis
8 test for continuous variables. We further divided hospitals into four groups according to the
9 percentage of their STEMI cases meeting the guideline recommended time to treatment goals
10 (meeting the metric in $\geq 99\%$ of cases; meeting the metric in 90 % to 98% of cases; meeting the
11 metric in 75% to 89% of cases; and meeting the metric in $<75\%$ of cases), and examined the
12 median and interquartile range (IQR) for time to treatment for each of the modes of presentation.
13 The American Heart Association-American College of Cardiology guidelines for STEMI ⁴
14 emphasize the importance of rapid access to PCI and provide time to treatment goals based on
15 the mode presentation. For patients transported by EMS, the goal is to achieve reperfusion with
16 primary PCI within 90 minutes of first medical contact (FMC). For patients presenting directly to
17 a PCI-capable hospitals (i.e. walk-ins), the Door-to-Balloon (D2B) time should be within 90
18 minutes from the time they enter the hospital to the initiation of PCI. In cases where a patient
19 initially arrives at a non-PCI-capable hospital, the guidelines recommend transfer to a PCI-
20 capable facility and performing PCI within 120 minutes from the FMC.

21 Based on the recommendations for time to treatment we looked at three different groups
22 according to their mode of presentation. For each mode of presentation, we first looked at
23 median time to reperfusion for patients who did not have NSD (the standard reporting for
24 GWTG performance metrics). Next, we looked at median time to reperfusion for patients with
25 NSD. Finally, we looked at median time to reperfusion for patients with NSD who did not also
26 have cardiogenic shock, cardiac arrest or the need for an LV support device. All statistical
27 analyses were performed by the AHA Data Science team using R (v4.2.0).

1 Results

2 Between January 1st, 2019 and December 31st, 2021, a total of 485,339 patients were enrolled
3 in GWTG-CAD registry. By applying the inclusion/exclusion criteria shown in Figure 1, 74,372
4 patients were finally included in the analysis. Among these 74,372 patients, 17,741(23.9%) had
5 NSD. The reasons for NSD are depicted in the Supplemental Table 1. Hospitals were able to
6 choose multiple reasons for delay and those reasons shown in the table were not mutually
7 exclusive. The most commonly reported reason for NSD was cardiac arrest and/ or need for
8 intubation, followed by “other reasons” and then difficulty crossing the culprit lesion. The
9 characteristics of patients are shown in Table 1. Patients with NSD were older, and more likely to
10 be female, of black race, and have significant comorbidities. They also had higher rate of cardiac
11 arrest prior to arrival, heart failure on FMC, and cardiogenic shock on FMC; and had a higher
12 social vulnerability index score (were more vulnerable from a socioeconomic standpoint) .

13 In-hospital mortality was significantly higher in those patients with NSD compared to patients
14 without NSD (15.4% vs 2.7%, $p < 0.01$). Table 2 depicts the unadjusted and adjusted odds for in-
15 hospital mortality among all patients with NSD and for those with NSD unrelated to cardiac
16 arrest, intubation, or the need for LV support device placement. After adjusting for clinical
17 demographics, baseline clinical variables and illness severity descriptors on presentation and
18 SVI, the adjusted odds ratio for in-hospital mortality remain significantly higher for patients with
19 any NSD (adjusted OR, 2.78 [95% CI, 2.54-3.04]) as well as for those with NSD unrelated to
20 cardiac arrest, the need for intubation, or the need for LV support device placement. (Adjusted
21 OR, 1.65 [95% CI, 1.48-1.84]).

22 Table 3 depicts the hospital characteristics by quartiles according to the percentage of patients
23 with reported NSD in the said hospital, with Q1 including those hospitals with the lowest
24 proportion of their STEMI patients with NSD and Q4 including hospitals with the highest
25 proportion of patients with NSD. Hospital-level analyses showed wide variations in reporting of
26 patients with NSD from 0% to 100% with an IQR of 17% to 28%. In Q4, the percent of patients
27 with NSD ranged from 28% to 100% of all patients included in the registry with an IQR of 31%
28 to 43%, while the ranges were much narrower in Q1, Q2 and Q3.

1 Table 4 depicts the number and proportion of patients with NSD , and the number of hospitals
2 and proportion of NSD categorized by the FMC-related performance metric for each mode of
3 transportation. More patients were treated in hospitals meeting the metrics $\geq 75\%$ (high-achieving
4 hospitals) than those meeting metrics $< 75\%$ (low-achieving hospital). A significantly greater
5 reporting of patients with NSD was noted in the high-achieving hospitals. Median FMC-to-
6 device time were consistently and significantly shorter in high achieving hospitals regardless of
7 the transportation mode (Table 5). High-performing hospitals demonstrated shorter FMC-to-
8 device times, irrespective of the designation of NSD. A shorter median FMC-to-device time was
9 seen when evaluating a group of patients excluding those who have NSD (standard reporting for
10 GWTG Performance Metric); in the group of patients with NSD and in those with NSD
11 unrelated to cardiac arrest and/or the need for intubation or emergent placement of an LV support
12 device.

13 Discussion

14 The current study is the most extensive analysis of NSD in patients with STEMI to date. We
15 observed that a large proportion of patients with STEMI have NSD, which is reported in
16 approximately one quarter of patients enrolled in the registry. The most common reported reason
17 for NSD was cardiac arrest and/or the need for intubation. As might be expected, patients with
18 NSD were older and had higher rates of associated comorbid conditions including cardiac arrest,
19 heart failure, and cardiogenic shock on FMC. Patients with NSD had a nearly three times greater
20 in-hospital mortality rate compared to those without NSD, even after adjusting for other co-
21 variables. Notably, delays unrelated to cardiac arrest, the need for intubation, or the need for
22 emergent placement of an LV support device were also associated with a higher adjusted
23 mortality compared with patients without NSD.

24 Our findings were consistent with previous studies that showed a worse outcome in
25 patients with NSD¹⁰, and a higher mortality regardless of the reason for delay. Since the early
26 days of PCI, an increase in door-to-balloon time has been correlated with worse outcomes^{7 18}
27 and this study support these findings. Although these earlier reports are derived from all STEMI
28 population including patients with NSD, quality initiatives that reward hospitals for timely
29 reperfusion often exclude patients with clinical or social factors that could delay treatment, as

1 these factors are viewed as outside the hospital's capacity to affect change. Yet these patients
2 with NSD (particularly those with cardiogenic shock) are often the ones that derive the greatest
3 benefit from timely reperfusion with data suggesting a correlation between door-to-balloon time
4 and mortality in patients with cardiogenic shock¹⁹. This information emphasizes the importance
5 of improving treatment times in all patients regardless of the presence of NSD, and the need to
6 shift our focus towards quality improvement efforts that are inclusive of all patients.

7 Although NSD is more frequently reported in high-achieving hospitals, those high-
8 performing hospitals have also demonstrated shorter median FMC-to-device times across all
9 modes of patient presentation, regardless of the NSD presence. Our findings are novel in that
10 they show high-performing hospitals consistently have better FMC-to-device times among all
11 STEMI population including patients with NSD. This is likely attributable to the vigorous
12 implementation of quality improvement activities, which have been shown to significantly
13 reduce perfusion times and sustain long-term improvements^{20,21}. The fact that these high-
14 achieving hospitals are recognized in the GWTG-CAG program indicates that they consistently
15 execute thorough quality improvement practices. These findings highlight the critical role of
16 ongoing quality improvement efforts in consistently achieving better outcomes for all patient
17 populations.

18 Our analysis is consistent with an earlier report from the Centers for Medicare and
19 Medicaid Services quality measurement initiative¹³ demonstrating that 28% of patients with
20 STEMI were excluded from the estimation of door-to-balloon time, although the rates of
21 exclusion from the NCDR registry in these same hospitals were much lower (12%) than the rates
22 we report. The rates of NSD we report in the current analysis are also considerably higher when
23 compared to a study from a nationwide registry of STEMI patients hospitalized in 2009 to 2011,
24 which showed that 15% of STEMI patients had NSD¹⁰. Notably, these rates continue to climb
25 over time. Most recently, the proportion of patients with STEMI excluded from analysis of
26 treatment times due to NSD in the GWTG-CAD registry increased from 19% to 24% between
27 2018 and 2021¹¹. There are a number of reasons to explain this increase in NSD. It is possible
28 that this increase in reported NSD reflects a growing burden of higher risk patients encountered
29 by healthcare system over the years with a larger percentage of patients with vascular disease,
30 complex anatomy, or cardiac arrest/cardiogenic shock referred for PCI in STEMI. Data from the

1 National Inpatient Sample from 2003-2016 has demonstrated increased age, and a growing rate
2 of peripheral vascular disease, and chronic kidney disease cardiogenic shock and other
3 comorbidities among patients undergoing PCI²². Furthermore, according to the US National
4 Inpatient Sample from 2004 to 2018, the number of patients hospitalized for cardiogenic shock
5 has tripled²³. While it is tempting to attribute the rise in reported NSD to the COVID-19
6 pandemic, which led to increased treatment times due to staffing shortage, and the need for
7 personal protective equipment (PPE), only 7% of patients in this report were coded with need for
8 PPE as the reason for delay.

9 It is also possible that some of the increase in reporting of NSD is a result of greater
10 administrative efforts to identify a reason for exclusion in those patients with prolonged times to
11 treatment (“gaming of the system”) since the hospitals’ measures of door-to-balloon time are tied
12 to public reporting and pay-for-performance^{13,24,25}. Similar to the previous regional analysis¹²,
13 our hospital-level data showed great variation in exclusion rates (0% to 100%) that appear
14 unlikely to be due to chance or differences in patient characteristics. Notably, a large proportion
15 of patients with NSD had a reason other than the provided explanations. Until recently, the other
16 reasons for delay were not routinely recorded and therefore, we do not have a detailed
17 description of all of the “other” reasons for delay reported by hospitals. However, a small
18 sampling of the recorded reasons for delays based on data collected in more recent years suggest
19 a wide variation in the “definition” used by hospitals to document NSD (Supplemental Table 2).
20 Alternatively, it is possible that high achieving hospitals having the resources and expertise to
21 provide timely care, are also those that manage the sickest patients which accounts for the greater
22 proportion of patients with NSD but also explains the overall shorter reperfusion times, even
23 when patients with NSD are included in the metric. This once again emphasizes the need to
24 evaluate treatment times in all patients, as this may be a better reflection of quality of care
25 provided by each hospital.

26 This study has several limitations. First, the GWTG-CAD registry is a self-reported
27 registry because the voluntary registry is designed to help participating hospitals to improve their
28 processes of care. Many of the data fields were not required to be completed as a condition of
29 submission, resulting in missing data. We include only patients with full data available, rather
30 than impute missing data fields, as the ability of available fields to predict missing data for

1 highly prognostic terms such as cardiac arrest was quite limited. While we adjusted covariates
2 including demographic characteristics, medical history, clinical presentation, insurance status,
3 and the SVI, it is still possible that unmeasured or residual confounding factors could have
4 influenced the results, potentially leading to an overestimation of the true effect, but not to a
5 degree likely to account for the very large observed mortality differences. Notwithstanding these
6 significant limitations, the data we present here represent 1 of 2 available contemporary registries
7 of STEMI care in the United States that provides an overview of recent practice.

8 Conclusions

9 In conclusion, NSD in patients with STEMI are common, are increasing and are
10 associated with higher in-hospital mortality. Although NSD are more frequently reported in high
11 achieving hospitals, those awarded hospitals have shorter median FMC-to-device time in all
12 modes of patient presentation regardless of the designation of NSD. This information supports
13 the importance of shifting our focus on evaluating and improving treatment times in all patients,
14 regardless of the presence of a reason for delay. We propose that future recognition awards be
15 based on data that is inclusive of all patients in measures of treatment times regardless of the
16 presence or absence of NSD.

17

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

References

1. Jacobs AK, Ali MJ, Best PJ, Bieniarz MC, Bufalino VJ, French WJ, Henry TD, Hollowell L, Jauch EC, Kurz MC, et al. Systems of Care for ST-Segment-Elevation Myocardial Infarction: A Policy Statement From the American Heart Association. *Circulation*. 2021;144:e310-e327. doi: 10.1161/CIR.0000000000001025
2. Jollis JG, Roettig ML, Aluko AO, Anstrom KJ, Applegate RJ, Babb JD, Berger PB, Bohle DJ, Fletcher SM, Garvey JL, et al. Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. *JAMA*. 2007;298:2371-2380. doi: 10.1001/jama.298.20.joc70124
3. Gersh BJ, Stone GW, White HD, Holmes DR. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? *JAMA*. 2005;293:979-986.
4. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145:e18-e114. doi: 10.1161/CIR.0000000000001038
5. Berger PB, Ellis SG, Holmes Jr DR, Granger CB, Criger DA, Betriu A, Topol EJ, Califf RM. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. *Circulation*. 1999;100:14-20.
6. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. *Circulation*. 2004;109:1223-1225. doi: 10.1161/01.CIR.0000121424.76486.20
7. McNamara RL, Wang Y, Herrin J, Curtis JP, Bradley EH, Magid DJ, Peterson ED, Blaney M, Frederick PD, Krumholz HM, et al. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2006;47:2180-2186. doi: 10.1016/j.jacc.2005.12.072
8. Krumholz HM, Herrin J, Miller LE, Drye EE, Ling SM, Han LF, Rapp MT, Bradley EH, Nallamothu BK, Nsa W, et al. Improvements in door-to-balloon time in the United States, 2005 to 2010. *Circulation*. 2011;124:1038-1045. doi: 10.1161/CIRCULATIONAHA.111.044107

- 1 9. Granger CB, Bates ER, Jollis JG, Antman EM, Nichol G, O'Connor RE, Gregory T,
2 Roettig ML, Peng SA, Ellrodt G, et al. Improving Care of STEMI in the United States
3 2008 to 2012. *J Am Heart Assoc*. 2019;8:e008096. doi: 10.1161/JAHA.118.008096
- 4 10. Swaminathan RV, Wang TY, Kaltenbach LA, Kim LK, Minutello RM, Bergman G, Wong
5 SC, Feldman DN. Nonsystem reasons for delay in door-to-balloon time and associated in-
6 hospital mortality: a report from the National Cardiovascular Data Registry. *J Am Coll*
7 *Cardiol*. 2013;61:1688-1695. doi: 10.1016/j.jacc.2012.11.073
- 8 11. Jollis JG, Granger CB, Zegre-Hemsey JK, Henry TD, Goyal A, Tamis-Holland JE,
9 Roettig ML, Ali MJ, French WJ, Poudel R, et al. Treatment Time and In-Hospital
10 Mortality Among Patients With ST-Segment Elevation Myocardial Infarction, 2018-
11 2021. *JAMA*. 2022;328:2033-2040. doi: 10.1001/jama.2022.20149
- 12 12. Cotoni DA, Roe MT, Li S, Kontos MC. Frequency of nonsystem delays in ST-elevation
13 myocardial infarction patients undergoing primary percutaneous coronary intervention
14 and implications for door-to-balloon time reporting (from the American Heart
15 Association Mission: Lifeline program). *Am J Cardiol*. 2014;114:24-28. doi:
16 10.1016/j.amjcard.2014.04.003
- 17 13. McCabe JM, Kennedy KF, Yeh RW. Defining unavoidable delays in primary
18 percutaneous coronary intervention: discordance among patients excluded from National
19 Cardiovascular Quality Registries. *J Am Heart Assoc*. 2014;3:e000944. doi:
20 10.1161/JAHA.114.000944
- 21 14. Nathan AS, Raman S, Yang N, Painter I, Khatana SAM, Dayoub EJ, Herrmann HC, Yeh
22 RW, Groeneveld PW, Doll JA, et al. Association Between 90-Minute Door-to-Balloon
23 Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice:
24 Insights From the Cardiac Care Outcomes Assessment Program (COAP) in Washington
25 State. *Circ Cardiovasc Interv*. 2020;13:e009179. doi:
26 10.1161/CIRCINTERVENTIONS.120.009179
- 27 15. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger
28 SM, Fang JC, Fesmire FM, Franklin BA, et al. 2013 ACCF/AHA Guideline for the
29 Management of ST-Elevation Myocardial Infarction: Executive Summary. *Circulation*.
30 2013;127:529-555. doi: 10.1161/CIR.0b013e3182742c84
- 31 16. American Heart Association, Recognition Criteria Documents.
32 [https://www.heart.org/en/professional/quality-improvement/get-with-the-](https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/quality-improvement-recognition-criteria)
33 [guidelines/quality-improvement-recognition-criteria](https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/quality-improvement-recognition-criteria). Accessed 10/20/2023.
- 34 17. CDC/ATSDR Social Vulnerability Index.
35 https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html. 2022.
- 36 18. Park J, Choi KH, Lee JM, Kim HK, Hwang D, Rhee TM, Kim J, Park TK, Yang JH,
37 Song YB, et al. Prognostic Implications of Door-to-Balloon Time and Onset-to-Door
38 Time on Mortality in Patients With ST -Segment-Elevation Myocardial Infarction Treated

- 1 With Primary Percutaneous Coronary Intervention. *J Am Heart Assoc.* 2019;8:e012188.
2 doi: 10.1161/JAHA.119.012188
- 3 19. Saito Y, Inohara T, Kohsaka S, Muramatsu T, Ishii H, Yamaji K, Amano T, Kobayashi Y,
4 Kozuma K, Investigators JPR. Door-to-Balloon Time and Mortality in STEMI With
5 Cardiogenic Shock: A Nationwide Registry. *JACC Asia.* 2024;4:421-422. doi:
6 10.1016/j.jacasi.2024.03.002
- 7 20. Nestler DM, Noheria A, Haro LH, Stead LG, Decker WW, Scanlan-Hanson LN, Lennon
8 RJ, Lim C-C, Holmes DR, Rihal CS, et al. Sustaining Improvement in Door-to-Balloon
9 Time Over 4 Years. *Circulation: Cardiovascular Quality and Outcomes.* 2009;2:508-513.
10 doi: 10.1161/CIRCOUTCOMES.108.839225
- 11 21. Parikh SV, Treichler DB, DePaola S, Sharpe J, Valdes M, Addo T, Das SR, McGuire DK,
12 de Lemos JA, Keeley EC, et al. Systems-Based Improvement in Door-to-Balloon Times
13 at a Large Urban Teaching Hospital. *Circulation: Cardiovascular Quality and Outcomes.*
14 2009;2:116-122. doi: 10.1161/CIRCOUTCOMES.108.820134
- 15 22. Alkhouli M, Alqahtani F, Kalra A, Gafoor S, Alhajji M, Alreshidan M, Holmes DR,
16 Lerman A. Trends in Characteristics and Outcomes of Patients Undergoing Coronary
17 Revascularization in the United States, 2003-2016. *JAMA Netw Open.* 2020;3:e1921326.
18 doi: 10.1001/jamanetworkopen.2019.21326
- 19 23. Osman M, Syed M, Patibandla S, Sulaiman S, Kheiri B, Shah MK, Bianco C, Balla S,
20 Patel B. Fifteen-Year Trends in Incidence of Cardiogenic Shock Hospitalization and In-
21 Hospital Mortality in the United States. *J Am Heart Assoc.* 2021;10:e021061. doi:
22 10.1161/JAHA.121.021061
- 23 24. Nallamotheu BK, Wang Y, Bradley EH, Ho KK, Curtis JP, Rumsfeld JS, Masoudi FA,
24 Krumholz HM. Comparing hospital performance in door-to-balloon time between the
25 Hospital Quality Alliance and the National Cardiovascular Data Registry. *J Am Coll*
26 *Cardiol.* 2007;50:1517-1519. doi: 10.1016/j.jacc.2007.07.010
- 27 25. Jha AK, Orav EJ, Epstein AM. The effect of financial incentives on hospitals that serve
28 poor patients. *Ann Intern Med.* 2010;153:299-306. doi: 10.7326/0003-4819-153-5-
29 201009070-00004

30

31

32

Figure 1. Flowchart of Cohort Selection for Patients with ST-segment Elevation Myocardial Infarction

GWTG-CAD, Get With the Guidelines–Coronary Artery Disease registry; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non ST-segment elevation myocardial infarction, PCI, percutaneous coronary intervention; AHA, American Heart Association, NSD, non-system reasons for delay




Table 1. Baseline Characteristics of Patients with and without Non-system reason for Delays

Variable	No report of Non system Delay	Non-system Delay	Total Patients	P-value
N (%)	56631 (76.1)	17741 (23.9)	74372	
Age, years (median, IQR)	62 (17)	64 (18)	62 (17)	<0.001*
Female (n, %)	15420 (27.2)	5430 (30.6)	20850 (28.0)	<0.001*
Race/Ethnicity (n, %)				
Non-Hispanic White	41838 (73.9)	12796 (72.1)	54634 (73.5)	<0.001*
Non-Hispanic Black	5971 (10.5)	2150 (12.1)	8121 (10.9)	<0.001*
Hispanic	4459 (7.9)	1359 (7.7)	5818 (7.8)	0.3637
Asian	2169 (3.8)	694 (3.9)	2863 (3.8)	0.6371
Other	2194 (3.9)	742 (4.2)	2936 (3.9)	0.0691
Insurance (n, %)				
Private/VA/CHAMPUS/Other	27711 (48.9)	7777 (43.8)	35488 (47.7)	<0.001*
Medicaid	5891 (10.4)	2210 (12.5)	8101 (10.9)	<0.001*
Medicare	14651 (25.9)	5305 (29.9)	19956 (26.8)	<0.001*
Self-pay/no insurance	4602 (8.1)	1331 (7.5)	5933 (8.0)	0.0078*
Other/not documented/UTD	3776 (6.7)	1118 (6.3)	4894 (6.6)	0.0895
Medical History (n, %)				
Cerebrovascular disease	2228 (3.9)	1076 (6.1)	3304 (4.4)	<0.001*
Diabetes mellitus	9809 (17.3)	3606 (20.3)	13415 (18.0)	<0.001*
Currently on dialysis	288 (0.5)	202 (1.1)	490 (0.7)	<0.001*
Hypertension	22798 (40.3)	8161 (46.0)	30959 (41.6)	<0.001*
Heart failure	1500 (2.6)	957 (5.4)	2457 (3.3)	<0.001*

Peripheral artery disease	1345 (2.4)	792 (4.5)	2137 (2.9)	<0.001*
Prior Myocardial Infarction	4806 (8.5)	1795 (10.1)	6601 (8.9)	<0.001*
Prior Coronary Artery Bypass Graft	1178 (2.1)	660 (3.7)	1838 (2.5)	<0.001*
Prior Percutaneous Coronary Intervention	5931 (10.5)	2137 (12.0)	8068 (10.8)	<0.001*
Dyslipidemia	18212 (32.2)	6133 (34.6)	24345 (32.7)	<0.001*
Active or prior smoking	21983 (41.1)	6476 (38.5)	28459 (40.5)	<0.001*
Heart Rate on FMC > 100 (n, %)†	8374 (15.2)	3619 (21.3)	11993 (16.6)	<0.001*
Systolic Blood Pressure on FMC < 90 (n, %)†	2318 (4.2)	2501 (14.7)	4819 (6.7)	<0.001*
Initial Serum Creatinine > 1.2 mg/dL (n, %)†	11733 (21.8)	5747 (34.3)	17480 (24.7)	<0.001*
Left Ventricular Function Assessment (n, %)†				
< 30 %	4008 (7.3)	2590 (15.6)	6598 (9.3)	<0.001*
30 - 39 %	8083 (14.8)	2882 (17.3)	10965 (14.7)	<0.001*
40 - 49 %	13471 (24.6)	3897 (23.4)	17368 (24.4)	0.0165*
50 - 59 %	18793 (34.4)	4697 (28.3)	23490 (32.9)	<0.001*
60 - 69 %	9981 (18.3)	2432 (14.6)	12413 (17.4)	<0.001*
> 70 %	330 (0.6)	126 (0.8)	456 (0.6)	0.0332*
Patient Characteristic on FMC (n, %)†				
Cardiac arrest prior to arrival	1097 (2.4)	2781 (18.2)	3878 (6.3)	<0.001*
Heart failure on FMC	3179 (5.8)	2192 (12.7)	5371 (7.4)	<0.001*
Cardiogenic shock on FMC	1805 (3.3)	3238 (18.7)	5043 (7.0)	<0.001*
Transportation mode to first facility (n, %) - Not transferred from another facility				
EMS -- Air	796 (1.4)	252 (1.4)	1048 (1.4)	0.9125
EMS -- Ground Ambulance	27550 (48.6)	10347 (58.3)	37897 (51.0)	<0.001

Walk-in	16936 (29.9)	3901 (22.0)	20837 (28.0)	<0.001
Transferred from another facility (n, %)	11349 (20.0)	3241 (18.3)	14590 (19.6)	<0.001
Social Vulnerability Index (SVI) percentile rank \geq 90th (n, %)†	2998 (5.7)	1140 (6.9)	4138 (6.0)	<0.001

Abbreviations: IQR, interquartile range; FMC, first medical contact; EMS, emergency medical systems.

*Indicates significant difference with the reference quartile (1st Quartile) by two-sample proportion test, 0.05 as the significance level.

† Percentage for variable with missing values are out of total non-missing value counts

Table 2 In-hospital Mortality and Risk Adjusted In-Hospital Mortality of Patients with or without non-system reason for delays

	In-hospital mortality (n, %)	Unadjusted		Adjusted for age, gender, race/ethnicities, medical history†, cardiac arrest prior to arrival, heart-failure on FMC, cardiogenic shock on FMC, heart rate on FMC, SBP on FMC, creatinine, and LVF assessment	Adjusted for age, gender, race/ethnicities, medical history†, cardiac arrest prior to arrival, heart-failure on FMC, cardiogenic shock on FMC, heart rate on FMC, SBP on FMC, creatinine, LVF assessment, Insurance status, and SES (Zip Code: Social vulnerability Index)		
		Odds Ratio [95% CI]	P-value	Odds Ratio [95% CI]	P-value	Odds Ratio [95% CI]	P-value
No report of non-system reason for delay	1544 (2.7)	Ref	Ref	Ref	Ref	Ref	Ref
Any Non-system reason for delay	2730 (15.4)	6.49 [6.00 7.02]	<0.0001	2.78 [2.54 3.04]	<0.0001	2.78 [2.54 3.04]	<0.0001
NSD unrelated to cardiac arrest, intubation, or the need for LV support device placement†	731 (6.6)	2.51 [2.26 2.78]	<0.0001	1.66 [1.49 1.85]	<0.0001	1.65 [1.48 1.84]	<0.0001

Abbreviations: FMC, first medical contact; SBP, systolic blood pressure; LVF, left ventricular function; SES, socioeconomic status, CI, confidence interval.

* Subjective non-system reason for delay includes difficult vascular access, patient delays in providing consent, difficulty crossing the culprit lesion, need for additional PPE/confirmed infectious disease, and other

† Adjusted medical history variables includes all medical history variables from Table 1

Table 3. Hospital characteristics grouped by quartiles based on non-systems delays rates for primary percutaneous coronary intervention (**4 tiles**)

Variable	All Hospitals	1st Quartile	2nd Quartile	3rd Quartile	4th Quartile
N	442	111	111	110	110
Exclusion rate due to NSD (%) (median, [IQR])	22.1 (11.4)	12.5 (5.7)	19.6 (2.5)†	24.8 (2.6)†	37.0 (12.5)†
Min – Max	0.0 – 100.0	0.0 – 16.7	16.8 – 22.1	22.1 – 28.1	28.1 – 100.0
25 th percentile, 75 th percentile	16.8, 28.1	8.9, 14.6	18.4, 20.9	23.4, 26.0	30.9, 43.4
Region (n, %)					
Eastern	134 (30.3)	32 (28.8)	27 (24.3)	42 (38.2)	33 (30.0)
Midwest	86 (19.5)	22 (19.8)	22 (19.8)	23 (20.9)	19 (17.3)
Southeast	75 (17.0)	21 (18.9)	22 (19.8)	11 (10.0)	21 (19.1)
Southwest	67 (15.2)	17 (15.3)	19 (17.1)	17 (15.5)	14 (12.7)
Western	80 (18.1)	19 (17.1)	21 (18.9)	17 (15.5)	23 (20.9)
Teaching Status (n, %)					
Major Teaching Hospital	74 (16.7)	17 (15.3)	12 (10.8)	20 (18.2)	25 (22.7)
Minor Teaching Hospital	288 (65.2)	77 (69.4)	74 (66.7)	72 (65.5)	65 (59.1)
Non-teaching Hospital	80 (18.1)	17 (15.3)	25 (22.5)	18 (16.4)	20 (18.2)
Ownership (n, %)					
Government	48 (10.9)	12 (10.8)	14 (12.6)	10 (9.1)	12 (10.9)
Non-profit	334 (75.6)	80 (72.1)	83 (74.8)	91 (82.7)	80 (72.7)
Private	60 (13.6)	19 (17.1)	14 (12.6)	9 (8.2)	18 (16.4)
Hospital Location (n, %)					
Rural	31 (7.0)	10 (9.0)	8 (7.2)	7 (6.4)	6 (5.5)
Urban	411 (93.0)	101 (91.0)	103 (92.8)	103 (93.6)	104 (94.5)

Bed Size of Hospital (n, %)					
0 – 299 Beds	247 (55.9)	63 (56.8)	73 (65.8)	60 (54.5)	51 (46.4)
300 – 499 Beds	106 (24.0)	28 (25.2)	24 (21.6)	23 (20.9)	31 (28.2)
500 + Beds	89 (20.1)	20 (18.0)	14 (12.6)	27 (24.5)	28 (25.5)

NSD, non-system reason for delay

The 1st Quartile includes the 25% of hospitals with the lowest NSD rates, and the 4th Quartile includes the 25% of hospitals with the highest NSD rates.

† Indicates significant difference with the reference quartile (1st Quartile) by two-sample proportion test, 0.05 as the significance level.

Continuous values are calculated by Dunn test with Bonferroni correction.

Table 4. Sample size and exclusion rate for each group in hospitals meeting the guideline recommendations for time to treatment metric.

	Hospitals meeting the metric <75%	Meeting the metric 75% and < 90%	Meeting the metric >= 90% and < 99%	Meeting the metric >= 99 %
EMS patients				
PATIENT LEVEL				
N of Patients	20382	39745	11765	2418
N of patients with NSD (N, %)	4187 (20.5)	9625 (24.2)*	3248 (27.6)*	658 (27.2)*
N of patients with NSD unrelated to cardiac arrest, intubation, or the need for LV support device placement (N, %)	2483 (12.2)	6052 (15.2)*	2148 (18.3)*	430 (17.8)*
HOSPITAL LEVEL				
N of Hospitals	133	201	65	33
Exclusion rate due to NSD (% , median)	20.5 (10.3)	22.3 (10.3)*	24.1 (12.2)*	25.0 (18.1)
Min – Max	0.0 – 56.4	0.0 – 74.6	2.4 – 98.1	0.0 – 55.9
25 th percentile, 75 th percentile	14.7, 25.0	17.7, 28.0	19.5, 31.7	16.7, 34.7
Walk-in patients				
PATIENT LEVEL				
N of Patients	1436	6155	11013	2229
N of patients with NSD (N, %)	229 (15.9)	1140 (18.5)*	2022 (18.4)*	507 (22.7)*
N of patients with NSD unrelated to cardiac arrest, intubation, or the need for LV support device placement (N, %)	168 (11.7)	875 (14.2)*	1479 (13.4)	374 (16.8)*
HOSPITAL LEVEL				
N of Hospitals	47	124	190	72
Exclusion rate due to NSD (% , median)	16.7 (16.8)	17.8 (13.4)	17.7 (12.8)	21.1 (14.6)
Min – Max	0.0 – 52.9	0.0 – 70.6	0.0 – 57.9	0.0 – 100.0
25 th percentile, 75 th percentile	9.8, 26.6	11.3, 24.7	11.2, 23.9	12.4, 27.1
Transfer patients				

PATIENT LEVEL				
N of Patients	28430	18540	7511	7661
N of patients with NSD (N, %)	6410 (22.5)	4441 (24.0)*	1885 (25.1)*	2080 (27.2)*
N of patients with NSD unrelated to cardiac arrest, intubation, or the need for LV support device placement (N, %)	3970 (14.0)	2847 (15.4)*	1217 (16.2)*	1284 (16.8)*
HOSPITAL LEVEL				
N of Hospitals	157	78	30	60
Exclusion rate due to NSD (% , median)	21.8 (11.9)	21.8 (10.9)	22.8 (10.4)	22.6 (14.7)
Min – Max	0.0 – 98.1	2.4 – 52.2	6.8 – 70.6	0.0 – 74.6
25 th percentile, 75 th percentile	16.1, 28.0	16.2, 27.2	18.4, 28.8	18.3, 33.0

Abbreviations: IQR, interquartile range; NSD, non-system reason for delay

*Indicates significant difference with the reference quartile (1st Quartile) by two-sample proportion, 0.05 as the significance level. Continuous values are calculated by Dunn test with Bonferroni correction.

Table 5. Perfusion time (Minutes) for different hospital tiers based on proportion of patients meeting the guideline recommendations for time to treatment metric.

	Hospital Tiers			
	Meeting the metric < 75%	Meeting the metric ≥ 75% and < 90%	Meeting the metric ≥ 90% and < 99%	Meeting the metric ≥ 99%
EMS Patients				
(N)	20382	39745	11765	2418
FMC-to-PCI time excluding patients with NSD (min, median, IQR) (Standard Reporting for GWTG Performance Metrics)	91 (34)	81 (29)*	76 (24)*	77 (25)*
FMC-to-PCI time including patients with a NSD unrelated to cardiac arrest, intubation, or the need for LV support device placement† (min, median, IQR)	94 (38)	85 (35)*	80 (32)*	80 (34)*
FMC-to-PCI time including all patients (min, median, IQR)	97 (41)	87 (38)*	83 (35)*	83 (41)*
Walk-in Patients				
(N)	1436	6155	11013	2229
Door-to-device time excluding patients with NSD (min, median, IQR)	86 (39)	75 (32)*	70 (26)*	67 (25)*
Door-to-device time including patients with a NSD unrelated to cardiac arrest, intubation, or the need for LV support device placement† (min, median, IQR)	89 (45)	78 (37)*	73 (29)*	70 (29)*
Door-to-device time including all patients (min, median, IQR)	90 (45)	78 (38)*	73 (31)*	70 (30)*
Transfer Patients				
(N)	28430	18540	7511	7661
FMC-to-PCI time excluding patients with NSD (min, median, IQR)	86 (36)	80 (31)*	79 (25)*	79 (27)*

FMC-to-PCI time including patients with a NSD unrelated to cardiac arrest, intubation, or the need for LV support device placement† (min, median, IQR)	90 (40)	84 (36)*	83 (33)*	82 (31)*
FMC-to-PCI time including all patients (min, median, IQR)	93 (44)	86 (40)*	86 (36)*	84 (34)*

Abbreviations: IQR, interquartile range; FMC, first medical contact; NSD, non-system reason for delay.

*Indicates significant difference with the reference quartile (1st Quartile) by two-sample proportion test, 0.05 as the significance level.

†NSD unrelated to cardiac arrest, intubation, or the need for LV support device placement includes difficult vascular access, patient delays in providing consent, difficulty crossing the culprit lesion, need for additional PPE/confirmed infectious disease, and other.

Supplementary Table 1. Patient characteristics by types of non-system reason for delays

Variable	Difficult Vascular Access	Cardiac Arrest and/ or need for intubation	Patient delays in providing consent	Difficulty crossing the culprit lesion	Emergent placement of LV support device	Need for additional PPE/confirmed infectious disease	Other
N	2203	6074	743	3497	943	1368	5156
Female (n, %)	833 (37.8)	1654 (27.2)	325 (43.7)	985 (28.2)	262 (27.8)	388 (28.4)	1645 (31.9)
Male (n, %)	1370 (62.2)	4420 (72.8)	418 (56.3)	2512 (71.8)	681 (72.2)	980 (71.6)	3511 (68.1)
Race/Ethnicity (n, %)							
Non-Hispanic White	1617 (73.4)	4422 (72.8)	508 (68.4)	2558 (73.1)	666 (70.6)	956 (69.9)	3629 (70.4)
Non-Hispanic Black	261 (11.8)	719 (11.8)	96 (12.9)	473 (13.5)	102 (10.8)	169 (12.4)	595 (11.5)
Hispanic	170 (7.7)	449 (7.4)	65 (8.7)	237 (6.8)	80 (8.5)	125 (9.1)	433 (8.4)
Asian	72 (3.3)	249 (4.1)	56 (7.5)	102 (2.9)	53 (5.6)	66 (4.8)	235 (4.6)
Other	83 (3.8)	235 (3.9)	18 (2.4)	127 (3.6)	42 (4.5)	52 (3.8)	264 (5.1)

Supplementary Table 2. Supplementary delay reason documentation, captured in the 2023 dataset

Supplementary delay reason documentation	N
CT to rule out pulmonary embolism or aortic dissection	1
Extended transport time	1
Head CT first because patient hit head on cement	1
Intra-Aortic Balloon Pump	1
Initial call was a BLS call, Code 2	1
Late presenting STEMI	1
Traffic	1
Vessels not expanding and closing	1
Awaiting family arrival	1
Phone consultation with cardiovascular surgeon	1
Septic shock	1

The variable specifying the other reasons is only available in the latest dataset (Jan 1, 2023 to Dec 31, 2023 with cohort size of N=76,191). The majority of non-system delay entries lacked specific reason documentation. This table encompasses all documented delay reasons in our database.